Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 33,004 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo / Placebo Clear all
Completed Phase 1Phase 2 Interventional

Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People

NCT00099645
View directory record Official record
Conditions
HIV Infections
Interventions
Mifepristone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
10
States / cities
Torrance, California • Washington D.C., District of Columbia • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 1 Interventional

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

NCT06810245
View directory record Official record
Conditions
Chronic Osteoarthritis Pain, Chronic Low Back Pain
Interventions
PIPE-791, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Marietta, Georgia • Hartsdale, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

NCT00368472
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Not applicable Interventional

L-carnosine for Schizophrenia

NCT00177177
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
L-carnosine (dietary supplement)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

TRADE-Testosterone Replacement and Dutasteride Effectiveness

NCT00194675
View directory record Official record
Conditions
Hypogonadism, Benign Prostatic Hyperplasia
Interventions
Dutasteride, Testosterone gel, Placebo dutasteride
Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

NCT03751657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

NCT00557401
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
XP19986 SR3, 20 mg QD, XP19986 SR3, 40 mg QD, XP19986 SR3, 60 mg QD, XP19986 SR3, 30 mg BID, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 1 Interventional

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

NCT00426712
View directory record Official record
Conditions
Hepatitis B
Interventions
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

NCT04918719
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Acetylcysteine, Dextrose in Water
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

NCT03066830
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
28
States / cities
Litchfield Park, Arizona • Peoria, Arizona • Greenbrae, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Not applicable Interventional Results available

Nutritional Therapy Interventions in Heart Failure

NCT03424265
View directory record Official record
Conditions
Heart Failure NYHA Class II
Interventions
EAA mixture, Placebo (whey protein)
Dietary Supplement
Lead sponsor
University of Arkansas
Other
Eligibility
60 Years to 89 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults

NCT01601600
View directory record Official record
Conditions
Skeletal Muscle
Interventions
BYM338, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 1, 2026, 5:00 PM EDT
Recruiting Not applicable Interventional

Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis

NCT06365892
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis (AIS)
Interventions
open-label placebo, Treatment as usual
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
10 Years to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Not applicable Interventional

Effects of Miracle Fruit Pill Application on Food Likings and Energy Intake in Diabetic or Prediabetic Patients

NCT05468411
View directory record Official record
Conditions
Diabetes, PreDiabetes
Interventions
Oral application of miracle fruit pill, Oral application of sugar candy
Other
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
45 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bayside, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 1, 2026, 5:00 PM EDT
Not listed Not applicable Interventional

Cranial Electrotherapy Stimulation (CES) for Soldiers With Combat-Related Symptoms

NCT00866411
View directory record Official record
Conditions
Combat Related Symptoms, Irritability, Anger
Interventions
cranial electrotherapy stimulation (CES) with Alpha-Stim, placebo
Procedure
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Fort Hood, Texas • Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2009 · Synced Oct 1, 2026, 5:00 PM EDT
Completed No phase listed Observational

Acamprosate: Genes Associated With Response

NCT00662571
View directory record Official record
Conditions
Alcoholism
Interventions
acamprosate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Results available

Trial of Carvedilol in Alzheimer's Disease

NCT01354444
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Carvedilol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

Patient Experience Study of Deoxycholic Acid Injection

NCT02007434
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic Acid Injection, Placebo, Cold Compress, Lidocaine / Epinephrine, Loratadine, Ibuprofen, Compression Chin Strap
Drug · Other
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Goals for Reaching Optimal Wellness: GROWell

NCT04449432
View directory record Official record
Conditions
Pregnancy Related, Gestational Weight Gain, Postpartum Weight Retention, Overweight and Obesity
Interventions
GROWell (Interactive Obesity Treatment Approach), Attention Support Control
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

NCT01163721
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Escondido, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Results available

Sancuso® for Gastroparesis: An Open Label Study.

NCT01989221
View directory record Official record
Conditions
Gastroparesis
Interventions
Sancuso®
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 3 Interventional

DMT310-009 Topical in the Treatment of Acne Vulgaris

NCT06090721
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
9 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Freemont, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 1, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Results available

High Dose Vitamin B1 to Reduce Abusive Alcohol Use

NCT00680121
View directory record Official record
Conditions
Alcoholism
Interventions
Benfotiamine, Placebo
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 1, 2026, 5:00 PM EDT
Terminated Early Phase 1 Interventional Results available

Nitrous TRD Bipolar Depression

NCT02757521
View directory record Official record
Conditions
Treatment- Resistant Bipolar Disorder, Bipolar Disorder, Bipolar Depressive Disorder
Interventions
Nitrous Oxide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 1, 2026, 5:00 PM EDT